Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 179-183

  Melenhorst, Jan J ^a,d   Castillo, Paul ^b   Hanley, Patrick J ^c   Keller, Michael D ^c   Krance, Robert A ^b   Margolin, Judith ^b   Leen, Ann M ^b   Heslop, Helen E ^b   Barrett, A John ^a   Rooney, Cliona M ^b   Bollard, Catherine M ^b,c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; TACROLIMUS; TRANSCRIPTION FACTOR E2A; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; TCF3 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOVIRUS INFECTION; ADOPTIVE TRANSFER; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHILD; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS INFECTION; EX VIVO STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; T LYMPHOCYTE; WHOLE BODY RADIATION; ADENOVIRIDAE; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CYTOLOGY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETICS; HAPLOTYPE; IMMUNOLOGY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION;

ADENOVIRIDAE; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4;

ADENOVIRIDAE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE MARROW TRANSPLANTATION; CHILD; CYTOMEGALOVIRUS; GENE DELETION; GENE EXPRESSION; GRAFT VS LEUKEMIA EFFECT; HAPLOTYPES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84920561066     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.192     Document Type: Article

References (35)

1. Hilden, JM, Dinndorf, PA, Meerbaum, SO, Sather, H, Villaluna, D, Heerema, NA et al.; Children's Oncology Group. (2006). Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 108: 441-451.
2. Ribera, JM, Ortega, JJ, Oriol, A, Bastida, P, Calvo, C, Pérez-Hurtado, JM et al. (2007). Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol 25: 16-24.
3. Saarinen-Pihkala, UM, Heilmann, C, Winiarski, J, Glomstein, A, Abrahamsson, J, Arvidson, J et al. (2006). Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol 24: 5750-5762.
4. Chakraverty, R, Eom, HS, Sachs, J, Buchli, J, Cotter, P, Hsu, R et al. (2006). Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 108: 2106-2113.
5. Weiden, PL, Flournoy, N, Thomas, ED, Prentice, R, Fefer, A, Buckner, CD et al. (1979). Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300: 1068-1073.
6. Weiden, PL, Sullivan, KM, Flournoy, N, Storb, R and Thomas, ED (1981). Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529-1533.
7. Gerdemann, U, Katari, UL, Papadopoulou, A, Keirnan, JM, Craddock, JA, Liu, H et al. (2013). Safety and clinical effcacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21: 2113-2121.
8. Gustafsson, A, Levitsky, V, Zou, JZ, Frisan, T, Dalianis, T, Ljungman, P et al. (2000). Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specifc cytotoxic T cells. Blood 95: 807-814.
9. Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA et al. (2010). Long-term outcome of EBV-specifc T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115: 925-935.
10. Leen, AM, Myers, GD, Sili, U, Huls, MH, Weiss, H, Leung, KS et al. (2006). Monoculture-derived T lymphocytes specifc for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160-1166.
11. Micklethwaite, KP, Clancy, L, Sandher, U, Hansen, AM, Blyth, E, Antonenas, V et al. (2008). Prophylactic infusion of cytomegalovirus-specifc cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modifed dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 112: 3974-3981.
12. Riddell, SR, Watanabe, KS, Goodrich, JM, Li, CR, Agha, ME and Greenberg, PD (1992). Restoration of viral immunity in immunodefcient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
13. Walter, EA, Greenberg, PD, Gilbert, MJ, Finch, RJ, Watanabe, KS, Thomas, ED et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
14. Heslop, HE, Brenner, MK and Rooney, CM (1994). Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331: 679-680.
15. Saglio, F, Hanley, PJ and Bollard, CM (2014). The time is now: moving toward virus-specifc T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 16: 149-159.
16. Doubrovina, E, Ofaz-Sozmen, B, Prockop, SE, Kernan, NA, Abramson, S, Teruya-Feldstein, J et al. (2012). Adoptive immunotherapy with unselected or EBV-specifc T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119: 2644-2656.
17. Hanley, PJ, Cruz, CR, Savoldo, B, Leen, AM, Stanojevic, M, Khalil, M et al. (2009). Functionally active virus-specifc T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114: 1958-1967.
18. Hanley, PJ, Shaffer, DR, Cruz, CR, Ku, S, Tzou, B, Liu, H et al. (2011). Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specifcity after stem cell transplantation. Cytotherapy 13: 976-986.
19. Kern, F, Faulhaber, N, Frömmel, C, Khatamzas, E, Prösch, S, Schönemann, C et al. (2000). Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 30: 1676-1682.
20. Weber, G, Caruana, I, Rouce, RH, Barrett, AJ, Gerdemann, U, Leen, AM et al. (2013). Generation of tumor antigen-specifc T cell lines from pediatric patients with acute lymphoblastic leukemia-implications for immunotherapy. Clin Cancer Res 19: 5079-5091.
21. Chessells, JM, Veys, P, Kempski, H, Henley, P, Leiper, A, Webb, D et al. (2003). Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 123: 396-405.
22. Melenhorst, JJ, Leen, AM, Bollard, CM, Quigley, MF, Price, DA, Rooney, CM et al. (2010). Allogeneic virus-specifc T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116: 4700-4702.
23. Melenhorst, JJ, Scheinberg, P, Williams, A, Ambrozak, DR, Keyvanfar, K, Smith, M et al. (2011). Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells. Biol Blood Marrow Transplant 17: 800-809.
24. Amir, AL, D'Orsogna, LJ, Roelen, DL, van Loenen, MM, Hagedoorn, RS, de Boer, R et al. (2010). Allo-HLA reactivity of virus-specifc memory T cells is common. Blood 115: 3146-3157.
25. Behrendt, CE, Rosenthal, J, Bolotin, E, Nakamura, R, Zaia, J and Forman, SJ (2009). Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 15: 54-60.
26. Elmaagacli, AH, Steckel, NK, Koldehoff, M, Hegerfeldt, Y, Trenschel, R, Ditschkowski, M et al. (2011). Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118: 1402-1412.
27. Fletcher, JM, Prentice, HG and Grundy, JE (1998). Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. J Immunol 161: 2365-2374.
28. Hermouet, S, Sutton, CA, Rose, TM, Greenblatt, RJ, Corre, I, Garand, R et al. (2003). Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma. Leukemia 17: 185-195.
29. Della Chiesa, M, Falco, M, Podestà, M, Locatelli, F, Moretta, L, Frassoni, F et al. (2012). Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood 119: 399-410.
30. Foley, B, Cooley, S, Verneris, MR, Pitt, M, Curtsinger, J, Luo, X et al. (2012). Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119: 2665-2674.
31. Savani, BN, Rezvani, K, Mielke, S, Montero, A, Kurlander, R, Carter, CS et al. (2006). Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107: 1688-1695.
32. Melenhorst, JJ, Scheinberg, P, Chattopadhyay, PK, Gostick, E, Ladell, K, Roederer, M et al. (2009). High avidity myeloid leukemia-associated antigen-specifc CD8+ T cells preferentially reside in the bone marrow. Blood 113: 2238-2244.
33. Gerdemann, U, Keirnan, JM, Katari, UL, Yanagisawa, R, Christin, AS, Huye, LE et al. (2012). Rapidly generated multivirus-specifc cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20: 1622-1632.
34. Zarkowsky, D, Lamoreaux, L, Chattopadhyay, P, Koup, RA, Perfetto, SP and Roederer, M (2011). Heavy metal contaminants can eliminate quantum dot fuorescence. Cytometry A 79: 84-89.
35. Melenhorst, JJ, van Luxemburg-Heijs, SA, Landegent, JE, Willemze, R, Fibbe, WE and Falkenburg, JH (1999). Aplastic anaemia in donor cells 14 years after bone-marrow transplant. Lancet 353: 2037-2038.